Effect of statins on low-density lipoprotein size: A new role in cardiovascular prevention? [3]

Southern Medical Journal

Volumn 99, Issue 9, 2006, Pages 1015-1016

  Rizzo, Manfredi ^a   Berneis, Kasper ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LETTER; MORBIDITY; MORTALITY; RISK ASSESSMENT; SMOKING; STATISTICAL SIGNIFICANCE;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; PARTICLE SIZE;

EID: 33748806798     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000235471.56184.77     Document Type: Letter

References (5)

1. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
2. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006;99:1-14.
3. Griffin BA, Caslake MJ, Yip B, et al. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59-67.
4. Rizzo M, Berneis K, Corrado E, Novo S. The significance of low-density-lipoproteins size in vascular diseases. Int Angiol 2006;25:4-9.
5. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? Int J Cardiol 2006;107:166-170.